Home > Healthcare & Medical Devices > Macular Degeneration Treatment Market

Macular Degeneration Treatment Market Size, COVID-19 Impact Analysis, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2022 – 2028

  • Report ID: GMI4306

Macular Degeneration Treatment Market size is poised to witness substantial growth between 2022 and 2028. Emerging aging population across the globe, coupled with the rising number of obese and cardiovascular patients, will fuel the market growth during the forecast timeline. Moreover, the growing population with retinal disorders and hypertension will also lead to growth trends in the industry.

Increasing indulgence in smoking and foods containing saturated fats may lead to macular degeneration and may change the industry outlook in the coming years. Race is also one of the factors causing AMD. As per a study by the Mayo clinic, Caucasian people are commonly affected by these diseases leading to growth in the North American region. Furthermore, growing R&D activities led to developments like the inception of CY-09, an experimental drug to protect the macula from inflammation and could reduce the occurrence of dry AMD will support industry growth in the coming years.

With respect to the disease indication segment, wet AMD is projected to showcase substantial expansion over the forecast timeframe. According to a study by Cleveland Clinic, around 15% of the suffering from AMD have Wet-AMD. Driven by the severity of the disease, several R&D activities like the introduction of biosimilars to treat AMD have made headlines in recent times.

The anti-VEGF segment may contribute appreciably to the market owing to their efficiency in treating Wet-AMD. According to the American Academy of Opthalmology (AAO), these drugs are effective in stabilizing the vision in about 90% of people who take it and further improve the vision in about one-third of patients.

Under the distribution channel segmentation, hospitals are more likely to become the growth drivers. Increased hospital visits after COVID-19 vaccination and reduced cases will foster the demand for treatment among the elderly. Alongside, the diagnosis and treatment of the disease require regular hospital visits spurring the industry trends.

The increasing cardiovascular patients and the majority of the Caucasian population will lead to further expansion. The emerging drug adoption for the treatment of these diseases and growing R&D will push the market share.

Few of the leading players contributing to the market share are Pfizer, Novartis, Ophthotech Corporation, Santen Pharmaceuticals, Neurotech Pharmaceuticals, Bayer, StemCells, Allergan, GlaxoSmithKline, Sanofi, and Valeant Pharmaceuticals. These firms are putting their efforts in growth fueling activities, mergers, collaborations, acquisitions to strengthen their market position and retain customer base.

An example would be the Sanofi’s recent investment of close to USD 60 million in Gyroscope. Presently, GT005, the latter’s lead investigational gene therapy, is being evaluated in Phase II clinical trials for treating age-related macular degeneration (AMD).

Impact of COVID-19 on macular degeneration treatment market progression

The COVID-19 has had a dissenting impact on the market. Travel and movement restriction on the public and the increased risk of infection significantly reduced the number of hospitals and clinical visits. However, the industry is anticipated to reach the pre-pandemic growth rates as AMD clinics are following the COVID safety norms to ensure the safety of patients. It has increased the footfall in the hospitals and clinics and may result in improved growth.

The market research report of macular degeneration treatment includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2017 to 2028 for the following segments:

Market, By Disease Indication

  • Dry Age-related Macular Degeneration (dAMD)
  • Wet Age-related Macular Degeneration (wAMD)

Market, By Drug Class

  • Anti-vascular Endothelial Growth Factor (VEGFs)
  • Others

Market, By Distribution Channel

  • Hospitals
  • Ophthalmic Clinics
  • Ambulatory Surgical Centers

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
  • Latin America
    • Mexico
    • Brazil
  • Middle East and Africa
    • Saudi Arabia
    • South Africa


What Information does this report contain?

Historical data coverage: 2017 to 2021; Growth Projections: 2022 to 2028.
Expert analysis: industry, governing, innovation and technological trends; factors impacting development; drawbacks, SWOT.
6-7 year performance forecasts: major segments covering applications, top products and geographies.
Competitive landscape reporting: market leaders and important players, competencies and capacities of these companies in terms of production as well as sustainability and prospects.

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Budget constraints? Get in touch with us for special pricing

Request Discount

Our Market Research Reports Include:

  • Market snapshot
  • Market Segmentation
  • Value Chain Analysis
  • Growth Dynamics
  • Potential Market Opportunities
  • Regulatory Overview
  • Technology Evolution
  • Innovation & Sustainability